These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30624769)

  • 1. Initiation of Pediatric Clinical Trials for Coagulation Factors: Application of Pharmacokinetics and Allometry to First-in-Pediatric Dose Selection.
    Mahmood I
    J Clin Pharmacol; 2019 Jun; 59(6):829-834. PubMed ID: 30624769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allometric extrapolation of factors VII, VIII and IX clearance in children from adults.
    Mahmood I
    J Thromb Haemost; 2012 Aug; 10(8):1609-13. PubMed ID: 22612736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.
    Edginton AN; Shah B; Sevestre M; Momper JD
    Clin Pharmacokinet; 2013 Aug; 52(8):693-703. PubMed ID: 23588537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
    Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
    Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.
    Mahmood I; Cheng A; Brauer E; Humeniuk R
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):767-775. PubMed ID: 26547922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents.
    Mahmood I; Tegenge MA
    J Clin Pharmacol; 2019 Feb; 59(2):189-197. PubMed ID: 30192373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Clearance of Monoclonal and Polyclonal Antibodies and Non-Antibody Proteins in Children: Application of Allometric Scaling.
    Mahmood I
    Antibodies (Basel); 2020 Aug; 9(3):. PubMed ID: 32764408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
    Björkman S
    Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
    Xu Y; Langevin BA; Zhou H; Xu Z
    J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants.
    Tegenge MA; Mahmood I; Jiang Z; Forshee R
    J Clin Pharmacol; 2018 Jul; 58(7):877-884. PubMed ID: 29489016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
    Shapiro AD; Korth-Bradley J; Poon MC
    Haemophilia; 2005 Nov; 11(6):571-82. PubMed ID: 16236106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
    Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
    JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Allometric Scaling and Salisbury Rule for the Prediction of Antimalarial Drugs for First-in-Pediatric Dose Selection.
    Mahmood I
    Eur J Drug Metab Pharmacokinet; 2023 Sep; 48(5):587-594. PubMed ID: 37566210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
    Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
    Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
    Björkman S
    Haemophilia; 2003 May; 9 Suppl 1():101-8; discussion 109-10. PubMed ID: 12709045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment on demand--in vivo dose finding studies.
    Escobar MA
    Haemophilia; 2003 Jul; 9(4):360-7. PubMed ID: 12828669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
    Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
    Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allometry Is a Reasonable Choice in Pediatric Drug Development.
    Liu T; Ghafoori P; Gobburu JV
    J Clin Pharmacol; 2017 Apr; 57(4):469-475. PubMed ID: 27649629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.